Cannabis in Adults with Cancer
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
Treatment
...al Communication and Educatio...
...ation 1.1Health systems and clinicians, i...
...n 1.2Given the high prevalence of cannabi...
...tion 1.3When adults with cancer use cannabis...
...ancer Treatmen...
...2.1Clinicians should recommend against use o...
...2.2Clinicians should recommend against use o...
...er Treatment-related Toxicity, Symptoms...
...mmendation 3.1...
...nol and nabilone] (EB, , M, Weak)34...
...C:CBD extract] (EB, , L, Weak)3499376...
...n 3.2Outside of a clinical trial, clinic...
...mmendation 3.3Evidence remains insuff...
...an In-depth History of Cannabis an...
...of Recommendations Pertaining to Use of...
...Safety AwarenessHaving trouble vie...
...e 1. Endocannabinoid System
...ves that cancer clinical trials are vital to i...